Compare Novo Nordisk A/S (NVO) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Wendys Co — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Wendys Co trades at $6.23 (market cap $1.19B). The key difference: Novo Nordisk A/S is far larger — about 138.9× Wendys Co's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Wendys Co for 77 Days on average.
| NVO | WEN | |
|---|---|---|
Market Cap | $165.31B | $1.19B |
Volume | 11,432,838 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $9.33 |
52-Week Low | $35.29 | $6.10 |
Typical Hold Time | 116 Days | 77 Days |
Enterprise Value | $179.56B | $4.92B |
Dividend Yield | 4.71% | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
WEN trades at $6.22, up 1.8% today, but remains near multi-year lows amid bearish technical signals and fundamental pressures. The stock shows low valuation multiples (P/E 9.45, P/S 0.54) and a high ROE of 108.04%, yet faces declining net income margins (7.58% in 2025) and negative sentiment from recent franchisee bankruptcies. Earnings have consistently beaten estimates, but same-store sales declines and high debt levels ($2.66B long-term) weigh on investor confidence.
The outlook is cautious; while valuation appears cheap and dividend yield offers income, competitive pressures, shrinking sales, and leveraged balance sheet pose significant risks. Analyst consensus is 'Hold' with a $7.58 price target, suggesting limited upside without operational turnaround under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
